Haleon plc (HLN)
| Market Cap | 40.43B -2.8% |
| Revenue (ttm) | 14.80B +1.2% |
| Net Income | 2.15B +6.6% |
| EPS | 0.49 +8.5% |
| Shares Out | 8.89B |
| PE Ratio | 18.79 |
| Forward PE | 15.97 |
| Dividend | $0.20 (2.16%) |
| Ex-Dividend Date | Aug 14, 2026 |
| Volume | 38,366,776 |
| Open | 9.23 |
| Previous Close | 9.23 |
| Day's Range | 9.09 - 9.36 |
| 52-Week Range | 8.38 - 11.28 |
| Beta | 0.29 |
| Analysts | Buy |
| Price Target | 10.40 (+13.66%) |
| Earnings Date | Jul 30, 2026 |
About HLN
Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company offers oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, and Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands. It also provides various over-the-counter products comprising nasal dr... [Read more]
Financial Performance
In 2025, Haleon's revenue was 11.03 billion, a decrease of -1.81% compared to the previous year's 11.23 billion. Earnings were 1.67 billion, an increase of 15.60%.
Financial numbers in GBP Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for HLN stock is "Buy." The 12-month stock price target is $10.4, which is an increase of 13.66% from the latest price.
News
Haleon downgraded to Hold from Buy at Jefferies
Jefferies downgraded Haleon (HLN) to Hold from Buy with a price target of 320 GBp, down from 400 GBp, following the company’s Q3 update. Haleon’s commitment to high single-digit organic…
Haleon price target lowered to 390 GBp from 460 GBp at Morgan Stanley
Morgan Stanley analyst Sarah Simon lowered the firm’s price target on Haleon (HLN) to 390 GBp from 460 GBp and keeps an Overweight rating on the shares. Published first on…
Broker tips: Haleon, GSK, Shell, Sainsbury, HSBC
Our broker tips, recommendations and target price updates of the week - Haleon, GSK, Shell, Sainsbury and HSBC
Haleon downgraded to Hold from Buy at Berenberg
Berenberg downgraded Haleon (HLN) to Hold from Buy with a price target of 365 GBp, down from 514 GBp. The firm cites the company’s reduced full year outlook for the…
Haleon removed from European Conviction List at Goldman Sachs
Goldman Sachs analysts removed Haleon (HLN) from the firm’s European Conviction List as part of its monthly update.
Haleon price target lowered to 290 GBp from 295 GBp at JPMorgan
JPMorgan lowered the firm’s price target on Haleon (HLN) to 290 GBp from 295 GBp and keeps an Underweight rating on the shares.
Haleon price target lowered to 390 GBp from 455 GBp at Citi
Citi lowered the firm’s price target on Haleon (HLN) to 390 GBp from 455 GBp and keeps a Buy rating on the shares.
Haleon price target lowered to 310 GBp from 390 GBp at RBC Capital
RBC Capital lowered the firm’s price target on Haleon (HLN) to 310 GBp from 390 GBp and keeps a Sector Perform rating on the shares.
Haleon upgraded to Hold from Sell at Deutsche Bank
Deutsche Bank analyst Tom Sykes upgraded Haleon (HLN) to Hold from Sell with a 310 GBp price target
Shares in consumer healthcare firm Haleon sink amid weak demand for cold and flu medicine
The FTSE 100 company said revenues rose 2.5% to £2.87bn in the three months to September 30, and it is on track for sales growth of around 2.5% in 2026.
Haleon plc Announces Commencement of £500m Share Buyback Programme
Haleon plc announced that it is commencing a share buyback programme to purchase ordinary shares of £0.01 each in the Company up to an aggregate consideration of £500 million. The purpose of the progr...
ASAIY or HLN: Which Is the Better Value Stock Right Now?
ASAIY vs. HLN: Which Stock Is the Better Value Option?
Haleon shares slide after targets cut due to weak cold and flu demand
The FTSE 100 company said revenues grew by 2.5% to £2.87 billion for the three months to September 30, compared with the same period last year.
What Haleon (HLN) Said on Its Q3 Earnings Call
Haleon NYSE: HLN said its third-quarter performance fell below expectations, citing weaker-than-anticipated North American growth, a softer cough, cold and flu season, a Chinese classification issue a...
Haleon CEO warns staff of 'difficult choices' ahead after sales miss, memo says
Haleon CEO Brian McNamara warned staff on Thursday that the British maker of Sensodyne toothpaste and Beechams cold medicines faced "difficult choices" in coming months, according to a memo seen by Re...
Haleon Earnings Call Transcript: Q3 2026
Q3 fell short as weak seasonal demand and China’s Centrum classification issue weighed on performance. Management expects operational changes and innovation to support stronger 2027 growth, while maintaining investment and disciplined capital allocation.
Haleon Earnings release: Q3 2026
Haleon released its Q3 2026 earnings on October 29, 2026, summarizing the period's financial results.
Haleon Slides: Q3 2026
Haleon has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on October 29, 2026.
Haleon Shares Dive After Advil Maker Cuts Guidance
Performance was held back by weaker sales in cough, cold and flu products, particularly with lower orders in North America.
Sensodyne maker Haleon cuts revenue growth forecast on weak flu season, China disruption
British consumer health company Haleon cut its annual organic revenue growth forecast on Thursday after weak demand for cold medicines and a regulatory setback in China weighed on sales.
UK Stock Market News: Lloyds Bank, IMI, Haleon
Improved outlook for IMI, Haleon's strong margins fuel £500m buy back, solid performance at Lloyds
Haleon Launches ‘Haleon Health House,’ a One-Day Interactive Wellness Pop-Up in Toronto
Limited-time experience invites Canadians to explore trusted health solutions, connect with experts and discover practical ways to support their wellbeing TORONTO, Oct. 19, 2026 (GLOBE NEWSWIRE) — On ...
Haleon Launches ‘Haleon Health House,' a One-Day Interactive Wellness Pop-Up in Toronto
Limited-time experience invites Canadians to explore trusted health solutions, connect with experts and discover practical ways to support their wellbeing Limited-time experience invites Canadians to ...
Only Excedrin Brings Digital Pet Nostalgia Back with a Headache You Can't Ignore
Nostalgia-fueled experience introduces Excedrin Rapid Relief, providing fast relief of tough pain that starts in as little as 15 minutes Key Takeaways: Excedrin is introducing My Little Headache, a no...